Correlation of KRAS status (wild type [wt] vs. mutant [mt]) with efficacy to first-line cetuximab in a study of cetuximab single agent followed by cetuximab + FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC)
暂无分享,去创建一个
J. Baselga | J. Tabernero | F. Ciardiello | C. Stroh | J. Nippgen | E. Martinelli | T. Macarulla | E. Rodríguez-Braun | A. Cervantes